VIDEO: NKF chief medical officer reviews late-breaking trials
Click Here to Manage Email Alerts
BOSTON — In this video from the National Kidney Foundation Spring Clinical Meetings, Joseph A. Vassalotti, MD, reviews results from late-breaking clinical trials.
Three abstracts were presented:
- Patiromer for the management of hyperkalemia in patients with heart failure with reduced ejection fraction receiving renin-angiotensin-aldosterone system inhibitors: Results from a prespecified chronic kidney disease subgroup analysis: The DIAMOND Trial from Matthew R. Weir, MD, University of Maryland School of Medicine;
- Hemoglobin efficacy and cardiovascular safety data from the ASCEND-ND, -D, and -ID trials from Ajay K. Singh, MD, Brigham and Women’s Hospital, Harvard Medical School; and
- APOL1 inhibition by VX-147 as a targeted therapy for APOL1-mediated kidney disease from Glenn Chertow, MD, Stanford University School of Medicine.
“In Matt Weir’s presentation, he talked about the use of patiromer to enable RAAS [renin-angiotensin-aldosterone system] blockade in patients with heart failure and reduced ejection fraction,” Vassalotti told Healio. “While patiromer is FDA approved, Matt highlighted some important features, particularly patients who are most likely to benefit from RAAS therapy are also the most likely to experience the side effect of hyperkalemia.”
In his presentation, Singh reviewed the results of the ASCEND-ND, -D, and -ID trials for daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat patients with anemia of chronic kidney disease. “Dr. Singh review the hemoglobin efficacy and cardiac safety from the ASCEND trials,” Vassalotti told Healio. “Unlike patiromer, daprodustat is not FDA approved yet so we will need to see how the FDA processed [the trial data].”
In the last presentation, Chertow presented data from a phase 2 trial involving patients with APOL1 kidney disease who used an experimental medication called VX-147. “The patients in the study saw a mean reduction in proteinuria from 2.2 to 1.2 grams,” Vassalotti told Healio. “That was an impressive reduction in proteinuria.
“This is an exciting study because it gets you to precision medicine,” Vassalotti continued. “We can use genetic studies to develop specific therapies that can help improve outcomes for our patients.”
Collapse
Read more about
Click Here to Manage Email Alerts